Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM.

Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386.

2.

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.

Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D.

Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.

PMID:
23197752
3.

Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.

Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ.

Sleep. 2014 Oct 1;37(10):1609-19. doi: 10.5665/sleep.4068.

4.

Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.

Patel KV, Aspesi AV, Evoy KE.

Ann Pharmacother. 2015 Apr;49(4):477-83. doi: 10.1177/1060028015570467. Epub 2015 Feb 9. Review.

PMID:
25667197
5.

Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.

Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, Dijk DJ.

Neuropsychopharmacology. 2012 Apr;37(5):1224-33. doi: 10.1038/npp.2011.310. Epub 2012 Jan 11.

6.

Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects.

Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J.

J Clin Pharmacol. 2015 Oct;55(10):1093-100. doi: 10.1002/jcph.523. Epub 2015 Jun 3.

PMID:
25903940
7.

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.

Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, Reiss DR, Cui D, Coleman PJ, Renger JJ.

J Neurogenet. 2011 Mar;25(1-2):52-61. doi: 10.3109/01677063.2011.566953. Epub 2011 Apr 8.

PMID:
21473737
8.

The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.

Bettica P, Squassante L, Zamuner S, Nucci G, Danker-Hopfe H, Ratti E.

Sleep. 2012 Aug 1;35(8):1097-104. doi: 10.5665/sleep.1996.

10.

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ.

Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.

PMID:
24680372
11.

Suvorexant: something new for sleep?

Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann S.

Acta Neuropsychiatr. 2015 Feb;27(1):53-5. doi: 10.1017/neu.2014.31. Epub 2014 Nov 14.

PMID:
25397996
12.

Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.

Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R, Alexander R.

J Psychopharmacol. 2012 Aug;26(8):1058-70. doi: 10.1177/0269881111408954. Epub 2011 Jul 5.

PMID:
21730017
13.

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.

Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J.

Sleep. 2015 Nov 1;38(11):1803-13. doi: 10.5665/sleep.5168.

14.

Orexin receptor antagonism: an ascending multiple-dose study with almorexant.

Hoever P, de Haas SL, Dorffner G, Chiossi E, van Gerven JM, Dingemanse J.

J Psychopharmacol. 2012 Aug;26(8):1071-80. doi: 10.1177/0269881112448946. Epub 2012 Jun 13.

PMID:
22695489
15.

Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.

Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, Lines C, Wagner JA, Troyer MD.

Respir Med. 2015 Mar;109(3):416-26. doi: 10.1016/j.rmed.2014.12.010. Epub 2015 Jan 5.

PMID:
25661282
16.

Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

Owen RT.

Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940. Review.

PMID:
26937493
17.

APD125, a selective serotonin 5-HT(2A) receptor inverse agonist, significantly improves sleep maintenance in primary insomnia.

Rosenberg R, Seiden DJ, Hull SG, Erman M, Schwartz H, Anderson C, Prosser W, Shanahan W, Sanchez M, Chuang E, Roth T.

Sleep. 2008 Dec;31(12):1663-71.

18.

Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.

Hoever P, Dorffner G, Beneš H, Penzel T, Danker-Hopfe H, Barbanoj MJ, Pillar G, Saletu B, Polo O, Kunz D, Zeitlhofer J, Berg S, Partinen M, Bassetti CL, Högl B, Ebrahim IO, Holsboer-Trachsler E, Bengtsson H, Peker Y, Hemmeter UM, Chiossi E, Hajak G, Dingemanse J.

Clin Pharmacol Ther. 2012 Jun;91(6):975-85. doi: 10.1038/clpt.2011.370.

19.

Suvorexant for the treatment of insomnia.

Jacobson LH, Callander GE, Hoyer D.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):711-30. doi: 10.1586/17512433.2014.966813. Review.

PMID:
25318834
20.

Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

Sleep Med. 2006 Aug;7(5):397-406. Epub 2006 Jul 3.

PMID:
16815744
Items per page

Supplemental Content

Write to the Help Desk